{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:10:15Z","timestamp":1793394615846,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European Alliance of Associations for Rheumatology","doi-asserted-by":"publisher","award":["QoC 022"],"award-info":[{"award-number":["QoC 022"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ard.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:07:49Z","timestamp":1760616469000},"page":"75-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-031X","authenticated-orcid":false,"given":"Antonis","family":"Fanouriakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Kostopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Houssiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Kouloumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia-Vasiliki","family":"Madenidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smaragdi","family":"Marinaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chiu","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rednic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana Sieiro","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Scire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Tamirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. K. Onno","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Welin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios T.","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.09.007_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ard.2025.09.007_bib0002","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0003","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0004","first-page":"736","article-title":"2019 update of the Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0006","unstructured":"EULAR SOPS Standard Operating Procedures for Task Forces [Internet]. The European Allianceof Associationsfor Rheumatology. Available from: https:\/\/www.eular.org\/web\/static\/lib\/pdfjs\/web\/viewer.html?file=https:\/\/www.eular.org\/document\/download\/996\/2a4b729e-cee6-4db8-99bf-aae42c61aa04\/909. Accessed January 15, 2024."},{"key":"10.1016\/j.ard.2025.09.007_bib0007","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.ard.2025.09.007_bib104","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ero.2025.07.006","article-title":"Management of systemic lupus erythematosus with kidney involvement: systematic literature review to inform the 2025 update of EULAR recommendations","volume":"3","author":"Kostopoulou","year":"2025","journal-title":"EULAR Rheum Open"},{"key":"10.1016\/j.ard.2025.09.007_bib0008","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0009","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.09.007_bib0010","series-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses","author":"Wells","year":"2019"},{"key":"10.1016\/j.ard.2025.09.007_bib0011","series-title":"Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document)","author":"H\u00f6lwick","year":"2011"},{"issue":"5","key":"10.1016\/j.ard.2025.09.007_bib0012","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/rheumatology\/keae278","article-title":"Can we predict kidney involvement in patients with systemic lupus erythematosus? A retrospective cohort study with independent validation","volume":"64","author":"Katechis","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.007_bib0013","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0014","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0015","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard-2023-224416","article-title":"EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.09.007_bib0016","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/ndt\/gfae280","article-title":"Hydroxychloroquine for all patients with lupus nephritis: yes","volume":"40","author":"Pappa","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ard.2025.09.007_bib0017","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0019","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Appel","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ard.2025.09.007_bib0020","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00467-020-04686-1","article-title":"Kidney outcomes for children with lupus nephritis","volume":"36","author":"Oni","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0021","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/ndt\/gfac304","article-title":"The influence of repeated flares in response to therapy and prognosis in lupus nephritis","volume":"38","author":"Perez-Arias","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ard.2025.09.007_bib0022","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ekir.2020.04.005","article-title":"Low-grade proteinuria does not exclude significant kidney injury in lupus nephritis","volume":"5","author":"De Rosa","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ard.2025.09.007_bib0023","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1093\/rheumatology\/keac067","article-title":"High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership","volume":"61","author":"Carlucci","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.007_bib0024","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2215\/CJN.01280122","article-title":"Short- and long-term progression of kidney involvement in systemic lupus erythematosus patients with low-grade proteinuria","volume":"17","author":"Wang","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0025","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1093\/rheumatology\/keaf015","article-title":"Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria","volume":"64","author":"Lu","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.ard.2025.09.007_bib0026","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2215\/CJN.10601016","article-title":"Clinical and Histopathologic characteristics associated with renal outcomes in lupus nephritis","volume":"12","author":"Rijnink","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0027","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/0961203318776109","article-title":"Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions","volume":"27","author":"Obri\u0219c\u0103","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ard.2025.09.007_bib0028","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/art.40724","article-title":"Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes","volume":"71","author":"Mackay","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0031","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/annrheumdis-2020-216965","article-title":"Lack of EULAR\/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis","volume":"79","author":"Moroni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0032","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: a systematic review and meta-analysis of the control arms of randomized controlled trials","volume":"76","author":"Figueroa-Parra","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0033","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/acr.24592","article-title":"Medium versus high initial prednisone dose for remission induction in lupus nephritis: a propensity score-matched analysis","volume":"74","author":"Tselios","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.09.007_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109296","article-title":"PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)","volume":"250","author":"Smith","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ard.2025.09.007_bib0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0036","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.09.007_bib0037","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0038","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2024bg7j9nj3","article-title":"MAJESTY: A phase 3, randomized, open-label, active comparator-controlled, multicenter study evaluating the efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: TH-OR92","volume":"35","author":"Fervenza","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0039","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0040","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.25007","article-title":"Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis","volume":"75","author":"Arriens","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ard.2025.09.007_bib0041","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2215\/CJN.0000000000000297","article-title":"Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria","volume":"19","author":"Menn-Josephy","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0042","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study","volume":"61","author":"Walsh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0043","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Walsh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0044","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1093\/rheumatology\/keab126","article-title":"Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study","volume":"60","author":"Lu\u00eds","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.ard.2025.09.007_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004437","article-title":"Attainment of EULAR\/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study","volume":"10","author":"Pappa","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.09.007_bib0046","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.3390\/jcm11175017","article-title":"Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-month median follow-up of an inception cohort","volume":"11","author":"Kapsia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0047","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0048","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2665-9913(23)00091-7","article-title":"Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study","volume":"5","author":"Rodziewicz","year":"2023","journal-title":"The Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0049","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2665-9913(21)00325-8","article-title":"Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative","volume":"4","author":"Andersen","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0050","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0051","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00467-017-3583-x","article-title":"Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis","volume":"32","author":"Basu","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0052","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.09.007_bib0053","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0054","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0055","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3899\/jrheum.170226","article-title":"Longterm data on disease flares in patients with proliferative lupus nephritis in recent years","volume":"44","author":"Yap","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0056","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0057","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"CJASN"},{"key":"10.1016\/j.ard.2025.09.007_bib0058","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.ard.2025.09.007_bib0059","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0060","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0061","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11926-023-01109-6","article-title":"Flares in lupus nephritis: risk factors and strategies for their prevention","volume":"25","author":"Banos","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.ard.2025.09.007_bib0062","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","article-title":"Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis","volume":"61","author":"Zen","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.ard.2025.09.007_bib0063","first-page":"keae381","article-title":"Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes","author":"Panagiotopoulos","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.007_bib0064","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.0000000000000365","article-title":"Immunosuppression withdrawal in patients with lupus nephritis: when, how, and for whom will it be safe?","volume":"35","author":"Frangou","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0065","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0066","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.kint.2020.10.037","article-title":"Improving medication adherence in patients with lupus nephritis","volume":"99","author":"Costedoat-Chalumeau","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0067","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial: efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ard.2025.09.007_bib0068","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"CJASN"},{"key":"10.1016\/j.ard.2025.09.007_bib0069","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0070","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","article-title":"Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis","volume":"59","author":"Parodis","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.ard.2025.09.007_bib0071","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000689","article-title":"Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis","volume":"9","author":"Gatto","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0072","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000721","article-title":"Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis","volume":"9","author":"Moroni","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0073","unstructured":"Per-protocol repeat kidney biopsy in incident cases of lupus nephritis. Re Bio Lup [Internet]. https:\/\/rebiolup.com\/. Accessed January 22, 2025."},{"key":"10.1016\/j.ard.2025.09.007_bib0074","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","article-title":"Histologic versus clinical remission in proliferative lupus nephritis","volume":"32","author":"Malvar","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ard.2025.09.007_bib0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy\u2013based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0076","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0077","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0078","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/acr.22857","article-title":"Does renin-angiotensin system blockade protect lupus nephritis patients from atherosclerotic cardiovascular events? A case-control study","volume":"68","author":"Tselios","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.09.007_bib0079","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0080","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0081","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.ard.2025.09.007_bib0082","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0083","first-page":"944","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"48","author":"Kello","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.09.007_bib0084","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ard.2025.09.007_bib0085","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1159\/000529229","article-title":"Antiphospholipid syndrome and kidney involvement","volume":"48","author":"De Simone","year":"2023","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ard.2025.09.007_bib0086","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0087","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12882-019-1560-2","article-title":"Clinical practice guideline on pregnancy and renal disease","volume":"20","author":"Wiles","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0088","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.007_bib0089","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.transproceed.2013.11.080","article-title":"Outcome of lupus nephritis after entering into end-stage renal disease and comparison between different treatment modalities: a nationwide population-based cohort study in Taiwan","volume":"46","author":"Wu","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ard.2025.09.007_bib0090","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/M18-1570","article-title":"Renal transplantation and survival among patients with lupus nephritis: a cohort study","volume":"170","author":"Jorge","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0091","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0092","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12882-020-01811-y","article-title":"Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation","volume":"21","author":"Swai","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ard.2025.09.007_bib0093","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.ajkd.2021.09.016","article-title":"Incidence of kidney replacement therapy and subsequent outcomes among patients with systemic lupus erythematosus: findings from the ERA registry","volume":"79","author":"Derner","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0094","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.ajkd.2021.07.013","article-title":"Dialysis outcomes for children with lupus nephritis compared to children with other forms of nephritis: a retrospective cohort study","volume":"79","author":"Wasik","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.kint.2021.09.012","article-title":"The lupus nephritis management renaissance","volume":"101","author":"Mejia-Vilet","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0096","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab (LUNAR) study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.09.007_bib0097","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.09.007_bib0098","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000221","article-title":"When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? results of the International Recommendation Implementation Study (IRIS)","volume":"2","author":"Gvozdenovi\u0107","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.09.007_bib0099","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/annrheumdis-2021-220438","article-title":"Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients","volume":"80","author":"Chavatza","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0100","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00296-023-05429-9","article-title":"Quality indicators and satisfaction with care in patients with systemic lupus erythematosus","volume":"44","author":"Serna-Pe\u00f1a","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0101","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/ard-2022-223016","article-title":"Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake","volume":"81","author":"Loza","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.007_bib0102","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.09.007_bib0103","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:51:23Z","timestamp":1773982283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725044127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0003496725044127"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.09.007","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}